KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $3.6 billion.

  • Amneal Pharmaceuticals' Liabilities and Shareholders Equity rose 4.01% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 billion, marking a year-over-year decrease of 0.08%. This contributed to the annual value of $3.5 billion for FY2024, which is 0.83% up from last year.
  • Amneal Pharmaceuticals' Liabilities and Shareholders Equity amounted to $3.6 billion in Q3 2025, which was up 5.17% from $3.4 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $4.0 billion in Q2 2022 and a low of $3.4 billion during Q1 2025.
  • Its 3-year average for Liabilities and Shareholders Equity is $3.5 billion, with a median of $3.5 billion in 2024.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first dropped by 9.81% in 2021, then grew by 4.01% in 2025.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Liabilities and Shareholders Equity stood at $3.9 billion in 2021, then fell by 3.56% to $3.8 billion in 2022, then declined by 8.60% to $3.5 billion in 2023, then climbed by 0.83% to $3.5 billion in 2024, then rose by 4.01% to $3.6 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $3.6 billion for Q3 2025, versus $3.4 billion for Q2 2025 and $3.4 billion for Q1 2025.